GlassScriptPhysician profile
Huynh Tran
NPI 1649566571
$13,586.20
in general payments reported to CMS, 2019-2025
36 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $521 · 2021: $813 · 2022: $813 · 2023: $7,857 · 2024: $1,357 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,498 · Honoraria: $2,875 · Consulting Fee: $1,620 · Travel and Lodging: $1,386 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,498.13 |
| Honoraria | $2,875.00 |
| Consulting Fee | $1,620.00 |
| Travel and Lodging | $1,386.47 |
| Education | $263.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $4,721.06 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $3,305.55 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $962.86 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $499.20 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $402.02 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Amarin Pharma, INC. | $346.23 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $298.17 | 2023-2024 | Linzess |
| Abbvie INC. | $292.70 | 2019-2024 | |
| Novo Nordisk INC | $261.03 | 2020-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $260.04 | 2023 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.15 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $249.10 | 2024-2025 | |
| Pfizer INC. | $221.72 | 2019-2025 | |
| Galderma Laboratories, L.P. | $169.20 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $157.18 | 2024 | Inpefa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $154.88 | 2023-2025 | |
| Ucb, INC. | $122.26 | 2024-2025 | Bimzelx, Cimzia |
| Mallinckrodt Enterprises LLC | $118.76 | 2019 | |
| Gilead Sciences, INC. | $117.06 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $92.98 | 2024-2025 | Gemtesa |
| Mallinckrodt Hospital Products INC. | $83.11 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $78.24 | 2022-2024 | Lupkynis |
| Madrigal Pharmaceuticals | $61.48 | 2025 | Rezdiffra |
| Scilex Pharmaceuticals INC. | $55.15 | 2024-2025 | |
| Almatica Pharma LLC | $51.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $34.12 | 2024 | Voquezna |
| Sun Pharmaceutical Industries INC. | $29.12 | 2022 | |
| Boston Scientific Corporation | $28.44 | 2019 | |
| Astellas Pharma US INC | $26.43 | 2025 | Veozah |
| Fresenius Kabi USA, LLC | $22.71 | 2023 | Idacio |
| Biohaven Pharmaceuticals, INC. | $19.74 | 2021 | |
| Alk-Abello, INC | $19.27 | 2023 | Odactra, Grastek, Ragwitek |
| Eisai INC. | $19.21 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.24 | 2021 | |
| Hikma Pharmaceuticals USA | $16.52 | 2019 | |
| Genentech USA, INC. | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huynh Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.